목적: 유방절제술 후 방사선치료와 항암화학요법을 시행한 유방암 환자의 치료성적을 연구하고자 하였다. 대상 및 방법: 1989년부터 1995년까지 유방절제술 후 여성 유방암 병기 II-III로 방사선치료를 받았던 83명의 환자를 대상으로 후향적 분석을 시행하였다. 연령 분포는 $23\~77$세였고 중앙 연령은 46세로 77명은 변형된 근치적유방절제술을, 5명은 근치적 유방절제술을, 1명은 단순유방절제술을 받았다. 80명($96\%$)의 환자에서 액와림프절 전이 소견을 보였고 병리학적 병기상 11명이 2기초, 23명이 2기말, 44명은 3기초, 5명은 3기말이었다. 방사선치료는 80명의 환자에서 "hocky-stick 조사문"을 사용하였고 방사선치료 선량의 중앙값은 일일 1.8 Gy, 총 50.4 Gy였다. 74명($89\%$)의 환자에서 항암화학요법이 병행되었으며, 54명($65\%$)의 환자에서 CMF 혹은 doxorubicin이 포함된 약제가 투여되었다. 추적기간은 $8\~17$개월로 중앙값은 82개월이었다. 결과: 5년 및 10년 전체생존율은 각각 $65\%$와 $49\%$이었다. 생존율에 대한 단변량 및 다변량분석에서 병기 2기와 항암화학요법을 병행한 환자군에서 유의한 생존율의 증가를 보여 주었다. 국소재발률은 $16\%$였으며, 방사선치료 후 $4\~84$개월(중앙값: 20개월) 사이에 발생하였다. 국소재발을 보인 13명 중 6명은 국소 재발 단독으로, 그 외 7명은 원격전이와 동시에 국소재발이 발생하였다. 방사선 치료시기와 관련하여 수술 후 6개월 이내에 방사선치료를 받았던 환자군 에서는 국소재발률이 $141\%$인 반면 6개월 이후에 방사선치료를 시행한 경우는 $27\%$였다(p=0.24). 국소재발과 관련하여 시행한 단변량 및 다변량 분석에서는 항암화학요법의 병행 유무가 가장 유의한 예후인자 였다. 그러나 방사선과 항암제의 병행 방법에 따른 생존율이나 국소재발률의 차이는 보이지 않았다. 전체 환자의 약 1/3에서 방사선치료 후 $2\~92$개월(중앙값: 21개월) 사이에 원격전이가 관찰되었고 가장 흔히 침범되는 장기는 골이었다. 17명($20\%$)의 환자에서 방사선폐렴이 확인되었고 방사선 완료 후 $2\~7$개월(중앙값: 3개월) 사이에 발생하였다 이중 $65\%$ (l1/17)의 환자에 서는 단순흉부촬영상 폐섬유화 소견이 잔존하였다. 결론: 본 연구를 통하여 유방절제술 후 방사선치료가 필요하였던 유방암 환자에서 항암제의 병행 치료는 방사선 단독치료에 비해 종양의 국소제어율과 생존율이 향상됨을 알 수 있었다.
목적: 유방절제술 후 방사선치료와 항암화학요법을 시행한 유방암 환자의 치료성적을 연구하고자 하였다. 대상 및 방법: 1989년부터 1995년까지 유방절제술 후 여성 유방암 병기 II-III로 방사선치료를 받았던 83명의 환자를 대상으로 후향적 분석을 시행하였다. 연령 분포는 $23\~77$세였고 중앙 연령은 46세로 77명은 변형된 근치적유방절제술을, 5명은 근치적 유방절제술을, 1명은 단순유방절제술을 받았다. 80명($96\%$)의 환자에서 액와림프절 전이 소견을 보였고 병리학적 병기상 11명이 2기초, 23명이 2기말, 44명은 3기초, 5명은 3기말이었다. 방사선치료는 80명의 환자에서 "hocky-stick 조사문"을 사용하였고 방사선치료 선량의 중앙값은 일일 1.8 Gy, 총 50.4 Gy였다. 74명($89\%$)의 환자에서 항암화학요법이 병행되었으며, 54명($65\%$)의 환자에서 CMF 혹은 doxorubicin이 포함된 약제가 투여되었다. 추적기간은 $8\~17$개월로 중앙값은 82개월이었다. 결과: 5년 및 10년 전체생존율은 각각 $65\%$와 $49\%$이었다. 생존율에 대한 단변량 및 다변량분석에서 병기 2기와 항암화학요법을 병행한 환자군에서 유의한 생존율의 증가를 보여 주었다. 국소재발률은 $16\%$였으며, 방사선치료 후 $4\~84$개월(중앙값: 20개월) 사이에 발생하였다. 국소재발을 보인 13명 중 6명은 국소 재발 단독으로, 그 외 7명은 원격전이와 동시에 국소재발이 발생하였다. 방사선 치료시기와 관련하여 수술 후 6개월 이내에 방사선치료를 받았던 환자군 에서는 국소재발률이 $141\%$인 반면 6개월 이후에 방사선치료를 시행한 경우는 $27\%$였다(p=0.24). 국소재발과 관련하여 시행한 단변량 및 다변량 분석에서는 항암화학요법의 병행 유무가 가장 유의한 예후인자 였다. 그러나 방사선과 항암제의 병행 방법에 따른 생존율이나 국소재발률의 차이는 보이지 않았다. 전체 환자의 약 1/3에서 방사선치료 후 $2\~92$개월(중앙값: 21개월) 사이에 원격전이가 관찰되었고 가장 흔히 침범되는 장기는 골이었다. 17명($20\%$)의 환자에서 방사선폐렴이 확인되었고 방사선 완료 후 $2\~7$개월(중앙값: 3개월) 사이에 발생하였다 이중 $65\%$ (l1/17)의 환자에 서는 단순흉부촬영상 폐섬유화 소견이 잔존하였다. 결론: 본 연구를 통하여 유방절제술 후 방사선치료가 필요하였던 유방암 환자에서 항암제의 병행 치료는 방사선 단독치료에 비해 종양의 국소제어율과 생존율이 향상됨을 알 수 있었다.
Purpose: To evaluate the treatment outcomes after postmastectomy radiotherapy (PMRT) and chemotherapy in patients with breast cancer. Materials and Methods: The PMRT were retrospectively analyzed in 83 patients with stage II-III female breast cancer treated between 1989 and 1995. The median age was ...
Purpose: To evaluate the treatment outcomes after postmastectomy radiotherapy (PMRT) and chemotherapy in patients with breast cancer. Materials and Methods: The PMRT were retrospectively analyzed in 83 patients with stage II-III female breast cancer treated between 1989 and 1995. The median age was 46 years (range, 23-77): Seventy-seven patients had modified radical mastectomies, 5 radical mastectomies and 1 simple mastectomy. Three patients ($4\%$) had pathologically negative axillae, and the remaining 80 ($96\%$) had positive axillae. Eleven, 23, 44 and 5 patients had pathological stages IIA, IIB, IIIA, and IIIB, retrospectively. Eighty ($96\%$) patients were treated with hockey-stick fields. The median dose of PMRT was 50.4 ey, in 1.8 Gy fractions. Adjuvant systemic chemotherapy was given to 74 patients ($89\%$). CMF-based or doxorubicin-containing regimens were given to 54 patients ($55\%$). The median follow-up time was 82 months (range, 8-171) after the mastectomy. Results: The 5 and 10-year overall survival rates for all patients were 65 and $49\%$, respectively. The univariate and multivariate analyses of the factors affecting the overall survival revealed the stage to be the most significant prognostic factor (p=0.002), followed by the combination of chemotherapy. Thirteen patients $16\%$ developed a LRF, at an interval of 4-84 months after radiotherapy, with a median of 20 months. The only significant prognostic factor affecting LRF was the combination of chemotherapy, in both the univariate and multivariate analyses. With respect to the sequence of chemoradiation, the sequence had no saatistical significance (p=0.90). According to the time interval from mastectomy to the onset of radiotherapy, the LRFR of the patients group treated by RT within or after 6 month postmastectomy 6 months were 14 vs. $27\%$ respectively (p=0.24). One third of the pa41en1s (26/83) developed distant metastasis, in 2-92 months, after radiotherapy, with a median of 21 months. The most commonly involved site was bone in 13 cases. The pathological staging was the only significant prognostic factor in both the univariate and multivariate analyses that affected distant failure. Radiological finding of radiation pneumonitis on a simple chest x-ray was shown in $20\%$ (17/83), with a time interval ranging from 2 to 7 months post-radiotherapy, with a median of 3 months. The stable lung fibrosis settled in 11 patients ($65\%$). Conclusion: It was concluded through this analysis that the combination of PMRT with in chemotherapy resulted in better overall survival and local control than PMRT alone in patients needing PMRT.
Purpose: To evaluate the treatment outcomes after postmastectomy radiotherapy (PMRT) and chemotherapy in patients with breast cancer. Materials and Methods: The PMRT were retrospectively analyzed in 83 patients with stage II-III female breast cancer treated between 1989 and 1995. The median age was 46 years (range, 23-77): Seventy-seven patients had modified radical mastectomies, 5 radical mastectomies and 1 simple mastectomy. Three patients ($4\%$) had pathologically negative axillae, and the remaining 80 ($96\%$) had positive axillae. Eleven, 23, 44 and 5 patients had pathological stages IIA, IIB, IIIA, and IIIB, retrospectively. Eighty ($96\%$) patients were treated with hockey-stick fields. The median dose of PMRT was 50.4 ey, in 1.8 Gy fractions. Adjuvant systemic chemotherapy was given to 74 patients ($89\%$). CMF-based or doxorubicin-containing regimens were given to 54 patients ($55\%$). The median follow-up time was 82 months (range, 8-171) after the mastectomy. Results: The 5 and 10-year overall survival rates for all patients were 65 and $49\%$, respectively. The univariate and multivariate analyses of the factors affecting the overall survival revealed the stage to be the most significant prognostic factor (p=0.002), followed by the combination of chemotherapy. Thirteen patients $16\%$ developed a LRF, at an interval of 4-84 months after radiotherapy, with a median of 20 months. The only significant prognostic factor affecting LRF was the combination of chemotherapy, in both the univariate and multivariate analyses. With respect to the sequence of chemoradiation, the sequence had no saatistical significance (p=0.90). According to the time interval from mastectomy to the onset of radiotherapy, the LRFR of the patients group treated by RT within or after 6 month postmastectomy 6 months were 14 vs. $27\%$ respectively (p=0.24). One third of the pa41en1s (26/83) developed distant metastasis, in 2-92 months, after radiotherapy, with a median of 21 months. The most commonly involved site was bone in 13 cases. The pathological staging was the only significant prognostic factor in both the univariate and multivariate analyses that affected distant failure. Radiological finding of radiation pneumonitis on a simple chest x-ray was shown in $20\%$ (17/83), with a time interval ranging from 2 to 7 months post-radiotherapy, with a median of 3 months. The stable lung fibrosis settled in 11 patients ($65\%$). Conclusion: It was concluded through this analysis that the combination of PMRT with in chemotherapy resulted in better overall survival and local control than PMRT alone in patients needing PMRT.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
대상 데이터
Bolus was used for all or part of the treatment of the chest wall as a compensator for the different chest wall thickness. Posterior axillary boost was used in 70 patients.
데이터처리
Follow-up time and time to failure were calculated from the date of operation. Actuarial overall survival, local control and distant failure rate was calculated using the Kaplan-Meier methods and statistical comparison was tested with a two-sided Log-rank test. Multivariate analyses were perfonned using a Cox proportional hazard model (SPSS v 11.
성능/효과
In conclusion, we find through this analysis that the combination of PMRT with chemotherapy results better overall survival and local control than PMRT alone.
32) Of notes, the combination of chemotherapy with PMRT was one of the most significant prognostic factor affecting overall survival in our analysis. Our results favored chemotherapy in that the combination of chemoradiation decreased the LRFR and also improved overall survival with the statistical significance.
Throughout our analysis, patients with delayed PMRT more than 6 months showed the tendency of higher LRFR and lower overall survival rate without statistically significant difference. With respect to sequence, overall survival of RT first or chemotherapy first group was 64% and 53%, respectively (p=0.45) and local control of both group was 82% in RT first group and 84% in chemotherapy first group, respectively (p=0.90). Our data failed to prove the importance of sequence of chemoradiation in the aspect of survival, local control and distant failure.
후속연구
Through this analysis, we hope to evaluate treatment outcomes of PMRT and chemotherapy in patients with stage II-Ⅲ breast cancer.
참고문헌 (35)
Overgaard M, Hansen PS, Ocergaad J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New Engl J Med 1997;337:949-955
Ragaz JR, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. New Engl J Med 1997;337:956-962
Harris JR, Halpin-Murphy P, MxNeese M, ndenhall NP, Morrow M, Robert NJ. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:989-990
Abdel-Wahb M, Wolfson A, Raub W, et al. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation. Int J Radiat Onco, Biol Phys 1998;40:875-880
Jabro G, Wazer DE, Ruthazer R, et al. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > 10 positive axillary nodes. Int J Rdiat Oncol Biol Phys 1999;44:273-280
Rexht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: Guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539-1569
Hardenbergh PH, Bentel GC, Prosnitz LR, Marks LB. Postmastectomy radiotherapy: toxicities and techniques to reduce them. Seminars in Radiation Oncology 1999;9:259-268
Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study. N Engl J Med 1989;329:485-490
Richards MA, O'Reilly SM, Howell A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol 1990;8:2032-2039
Bechholz TA, Austin-Seymour MM, Moe RE, et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 1993;26:23-35
Recht A, Come S Gelman R, et al. Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage node-positive breast cancer: sequencing, timing, and outcome. J Clin Oncol 1991;9:1662-1667
Hartsell W. Recine D, Griem K, Murthy AK. Delaying the initiation of intact breast irradiation for patients with lymph node positive breast increases the risk of local recurrence. Cancer 1995;76:2497-2503
Recht A, Come SE, Henderdson IC, et al. The sequencin of chemotherapy and radiation therapy after conservative surgery for patients with early-stage breast cancer. New Eng J Med 1996;334:1356-1361
American, jonit Committee on Cancer. Breast. In: Beahrs OH, Henson DE, Hutter RVP, et al, eds. Manual for staging of cancer, ed 4. Philadelphia, JB Lippincott, 1992:149.
Early Berast Cancer Trialists' Collabrative Gropu. Effects of radiotherapy in early breast cancer. An overview of the randomized trials. N Engl J Med 1995;333:1444-1455
Host H, Brennhoud IO, Loeb M. Post-operative radiotherapy in breast cancer-Long-term results from the Oslo study Int J Radiat Oncol Biol Phys 1986;12:727-732
Jones JM, Ribeiro GG, Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy. Clin Radiol 1989;40:204-208
Haybittle J, Brinkley D, Houghton J, A'Hern RP, Baum M, Postoperative radiotherapy and late mortality: Evidence rom the Cancer Research Campaign trial for early breast cancer. Br Med J 1989;298:1611-1614
Fisher B, Slack NH, Cavanaugh PJ, Gardner B, Raudin RG. Post-operative in the treatment of breast cancer: Results of the NSABP clinical trial. Ann Surg 1970;172:711-730
Levitt SH, Fletcher BH, Trials and tribulations: Do clinical trials prove that irradiation increases cardiac and secondary cancer mortality in the breast cancer patient? Int J Radiat Oncol Biol Phys 1991;20:523-527
Overgaard M, Hansen PS, Overgaaed J, et all. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b trial. New Engl J Med 1997;337:949-955
Overgaard Mm, JensenM-B, Overgaard J et al. Randomized controlled trial evaluating postoperative radiothearpy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: report from the Danish Breast Cancer Cooperative Group DBCG 82c Trial. Lancet 1999;353:1641-1648
Ragaz j, Jackson SM, LE N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. New Engl J Med 1997;337:956-962
Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A metaanalysis. J Clin Oncol 2000;18:1220-1229
Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histological status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-772
Haagensen cD. Disease of the breast, 3rd edition. Philadelphia, PA:WB Saunders Co; 1986
Fletcher G H, McNeese M D, Oswald MJ. Long-range results for breast cancer patients treated by radical mastectomy and post-operative radiation without adjuvant chemotherapy: An update. Int J Radiat Oncol Biol Phys 1989;17:11-14
Fowble B, Glick J, Goodman R. Radiotherapy for the prevention of local-regional recurrence in high risk patients postmastectomy receiving adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 1988;15:627-631
Shin HS, Suh CO. Treatment results of adjuvant radiotherapy and chemotherapy in breast cancer patients with positive axillary nodes. J Korean Soc Ther Radiol Onco 2000;18:265-276
Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-942
Harris JR, Morrow M. Local management of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Disease of the breast. Philadelphia: Lippincott-Raven Co. 1996:487-547
Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate 5-fluorouracil (M F) for the treatment of node negative breast cancer patients with estrogen- receptornegative tumors: eight-year results from NSABP B-13 and first report of findings from NSABP B-19 comparing M F with conventional CMF. J Clin Oncol 1996;14:1982-1992
Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy for patients with early stage breast cancer: Updated results of a prospective randomized trial. Int J Radiat Onco, Biol Phys 2001;51(S):2-3
Harris JR, Hellman S. Put the 'hocky stick' on ice. Int J Radiat Onco, Biol Phys 1988;14:497-499
Paszat LF, Mackillop WJ, Groome PA et al. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology, and End-Results cancer registries. J Clin Oncol 1998;16:2632-2640
※ AI-Helper는 부적절한 답변을 할 수 있습니다.